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Summary
Suppressor of cytokine signaling (SOCS) proteins are
indispensable negative regulators of cytokine-stimu-
lated Janus kinase (JAK)-signal transducer and activa-
tor of transcription (STAT) signaling pathways. SOCS
proteins (SOCS1–7 and CIS) consist of a variable N-
terminal region, a central Src homology-2 (SH2) do-
main, and a C-terminal SOCS box. The N-terminal
region in SOCS1 and SOCS3 includes the so-called
kinase inhibitory region that has been shown to inhibit
the catalytic activity of JAK2. Here, we present a crystal
structure at 2.0 A˚ resolution of the N-terminally ex-
tended SH2 domain of SOCS3 in complex with its phos-
phopeptide target on the cytokine receptor gp130. The
structure reveals that major insertions in the EF and BG
loops of the SOCS3 SH2 domain are responsible for
binding to gp130 with high affinity and specificity. In
addition, the structure provides insights into the possi-
ble mechanisms by which SOCS3 and SOCS1 inhibit
JAK2 kinase activity.
Introduction
Cytokines such as ciliary neurotrophic factor, leukemia
inhibitory factor (LIF), interleukin-2 (IL2), IL6, leptin,
and erythropoeitin bind to receptors that activate Janus
kinase (JAK)-signal transducer and activator of tran-
scription (STAT) signaling pathways, resulting in tran-
scriptional upregulation of genes that control cellular
proliferation, differentiation, and survival (Ihle and Kerr,
1995). In a classic negative feedback system, cytokine
stimulation also upregulates transcription of genes en-
coding SOCS proteins (Alexander and Hilton, 2004).
The SOCS protein family consists of eight members,
SOCS1–7 and CIS, that possess a variable N-terminal
region, a central SH2 domain, and a C-terminal SOCS
box (Hilton et al., 1998).
Through their SH2 domains, SOCS proteins are re-
cruited to specific phosphotyrosine residues in acti-
vated cytokine receptors or in JAKs. Downregulation
of signaling pathways by SOCS proteins can occur by
at least three distinct mechanisms. First, the SOCS
box is capable of recruiting the elongin BC complex to
target proteins for ubiquitination and subsequent pro-
teasomal degradation (Alexander and Hilton, 2004).
Second, SOCS1 and SOCS3 contain a region N-terminal
to the SH2 domain, the so-called kinase inhibitory re-
*Correspondence: hubbard@saturn.med.nyu.edugion, that has been shown to inhibit the catalytic activity
of JAK2 (Sasaki et al., 1999; Yasukawa et al., 1999).
Third, SOCS proteins can compete with SH2-containing
positive factors for binding to phosphotyrosine residues
on activated cytokine receptors.
Gene deletion studies in mice have provided impor-
tant insights into the in vivo function and specificity of
SOCS proteins (Alexander and Hilton, 2004). SOCS32/2
mice are not viable (midgestational lethal), owing to pla-
cental abnormalities that are thought to be caused by
dysregulated LIF signaling (Roberts et al., 2001; Takaha-
shi et al., 2003). Targeted gene deletion in the liver of
mice has demonstrated that SOCS3 is important for
downregulation of IL6 signaling pathways (Croker
et al., 2003). The site of interaction of SOCS3 with
gp130, the common cytokine receptor for IL6 and LIF,
has been mapped to pTyr757 (Nicholson et al., 2000;
Schmitz et al., 2000). SOCS3 has also been reported to
interact with JAK2 (Sasaki et al., 1999), the leptin recep-
tor (Bjorbak et al., 2000; Eyckerman et al., 2000), the
erythropoietin receptor (Sasaki et al., 2000), and the in-
sulin receptor (Emanuelli et al., 2000; Ueki et al., 2004).
To elucidate the molecular basis for phosphotyrosine
recognition by SOCS3, we have determined the crystal
structure of the N-terminally extended SOCS3 SH2 do-
main in complex with a phosphopeptide representing
pTyr757 in gp130. The structure provides the molecular
basis for the high-affinity interaction between SOCS3
and gp130, and it offers insights into the mechanisms
by which SOCS3 and SOCS1 negatively regulate JAK2
signaling.
Results and Discussion
Crystal Structure of SOCS3-gp130(pTyr757)
For structural studies, a murine SOCS3 construct was
engineered that lacks the nonconserved N-terminal 14
residues and the C-terminal 40 residue SOCS box, but
possesses, along with the SH2 domain (residues 42–
185), the kinase inhibitory region (residues 22–31) and
the N-terminal SH2 domain extension (residues 32–41).
The SOCS3 construct also contains a 23 residue dele-
tion (residues 131–153) within the BG loop of the SH2
domain (SH2 domain nomenclature follows that of Eck
et al. [1993]). This region in SOCS3 contains a PEST se-
quence (Babon et al., 2005), which is present in mamma-
lian forms of SOCS3, but is missing in other vertebrate
forms. The introduced 23 residue deletion is based on
a comparison between the zebrafish and mammalian
SOCS3 sequences. This form of SOCS3 will be referred
to below as SOCS3D.
An 11 residue phosphopeptide based on the
sequence surrounding Tyr757 in murine gp130,
753STVEpYSTVVHS, was used in cocrystallization trials
with SOCS3D. As measured by isothermal titration
calorimetry, this phosphopeptide binds to SOCS3 with
unusually high affinity for an SH2-phosphopeptide inter-
action: Kd = w70 nM with SOCS3D (w80 nM with an
intact BG loop) (Figure S1; see the Supplemental
Data available with this article online). Crystals of the
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tained at pH 6.5 with one complex in the asymmetric
unit. The structure was initially solved by molecular re-
placement and was subsequently verified with experi-
mental phases from a mercury-derivatized crystal (see
Experimental Procedures). The structure has been re-
fined at 2.0 A˚ resolution to an R value of 24.2% (Rfree
of 27.7%). Data collection and refinement statistics are
given in Table 1.
The crystal structure reveals that the SOCS3 SH2 do-
main adopts a canonical SH2 domain architecture (Kur-
iyan and Cowburn, 1997), with a central, four-stranded
b sheet (bA/bG, bB, bC, and bD), flanked by two a helices
(aA and aB) (Figure 1A). The N-terminal extension, pres-
ent in SOCS1–3 and CIS, forms a 14 residue a helix (aN),
which packs against portions of bB, bC, aB, and the DE
loop on the backside (opposite the phosphotyrosine
binding surface) of the SH2 domain (Figure 1A). Resi-
dues 15–28, which include residues 22–28 of the kinase
inhibitory region, are disordered.
All 11 residues of the phosphopeptide are ordered in
the structure, although most of the contacts with the
SH2 domain are made by pTyr757 and the residues C-
terminal to pTyr757. Indeed, a C-terminal portion of
the phosphopeptide is ‘‘enveloped’’ by the EF and BG
loops (Figure 1B). The total buried surface area in the
SOCS3 SH2-gp130 phosphopeptide complex is
large—1746 A˚2—compared to 987 A˚2 for the Src SH2-
phosphopeptide complex (Waksman et al., 1993) (PDB
code 1SPS) and 1339 A˚2 for the SHP2 N-terminal SH2-
phosphopeptide complex (Lee et al., 1994) (PDB code
1AYA); the SH2 domains of SOCS3 and SHP2 have
been shown to have overlapping specificities (De Souza
et al., 2002). The only known SH2-phosphopeptide in-
teraction with a larger buried surface area is the SAP
SH2-SLAM phosphopeptide complex (Poy et al., 1999),
with 1821 A˚2 buried (PDB code 1D4W). Despite the
larger buried surface area, the measured affinity of the
SAP SH2-phosphopeptide interaction (Kd = w150 nM)
(Li et al., 1999) is less than that of SOCS3-gp130
(Kd =w70 nM).
The specific contacts between the SOCS3 SH2 do-
main and the gp130 phosphopeptide are extensive (Fig-
ure 2) and explain the high affinity and specificity of this
SH2-phosphopeptide interaction. The phosphate group
of pTyr757 binds in the canonical phosphate binding
pocket of the SOCS3 SH2 domain, salt bridged to
SH2-invariant Arg71 (bB5) (Figure 2A). Like SHP2, but
unlike other SOCS proteins, the SOCS3 SH2 domain
contains a glycine (Gly53) at position aA2 rather than
the semiconserved arginine. As a consequence, the po-
sition of the phosphate group relative to the phenolic
ring of the phosphotyrosine is inverted, as observed in
the SHP2 SH2-phosphopeptide structure (Lee et al.,
1994). Arg94 in bD (bD6) is also salt bridged to the phos-
phate group, and its guanidinium group stacks with the
phenolic ring of pTyr757. In total, seven direct hydrogen
bonds are made to the phosphate group by SH2 domain
residues (Figures 2A and 2C).
N-terminal to pTyr757 of the gp130 phosphopeptide,
Val755 (P22 residue relative to pTyr757) makes van
der Waals contacts with Gly53 (aA2), the position usually
occupied in SH2 domains by an arginine. C-terminal to
the phosphotyrosine, the P+3 residue, Val760, is situ-ated in the canonical P+3 binding pocket of the SH2 do-
main, formed between the EF and BG loops and be-
tween bD and aB. The EF loop in the SOCS3 SH2
domain contains a 7 residue insertion relative to Src
and SHP2 (see Figure 3A for alignment) that ‘‘drapes’’
over the phosphopeptide in the structure (Figure 1A,
right) and contributes six hydrogen bonds to the interac-
tion (Figures 2B and 2C). In contrast, for most SH2 do-
mains (e.g., Src and SHP2), the EF loop does not make
appreciable contact with the phosphopeptide. The EF
loop in the SAP SH2 domain, which also contains a siz-
able (6 residue) EF loop insertion, makes three hydrogen
bonds with the phosphopeptide (Poy et al., 1999). Of
particular note for SOCS3, recognition of His762, the
P+5 residue of the phosphopeptide, is achieved through
side chain hydrogen bonding with Ser106 in the EF
loop (EF2) and with Tyr127 in aB (aB9) (Figures 2B and
2C). A salt bridge between Asp107 (EF3) and Arg109
(EF5) within the EF loop likely functions to stabilize its
conformation.
The BG loop in SOCS3 is of exceptional length, being
37 and 34 residues longer than in Src and SHP2, respec-
tively (Figure 3A). The beginning of the BG loop, just after
the end of aB, is disordered in the structure. This is the
position in SOCS3 that contains the 23 residue PEST
sequence, which is deleted in our construct. In the C-ter-
minal half of the BG loop, two segments form short,
Table 1. X-Ray Data Collection and Refinement Statistics
Data Collection Native EMP Derivative
Bragg spacings (A˚) 50–2.0 50–2.3
Observations 34,560 45,998
Unique reflections 9,956 12,119
Redundancy 3.5 3.8
Completenessa (%) 99.5 (99.4) 99.5 (100)
Rsym
a,b (%) 5.6 (32.3) 5.8 (31.9)
<I/sI> 15.6 16.3
Phasingc
Figure of merit (50–2.5 A˚,
MLPHARE)
0.44








Rmsd bond lengths (A˚) 0.010
Rmsd bond angles () 1.27
Rmsd B factorsf (A˚2)
(main/side chain)
0.9/1.6





a Values in parentheses are for the highest-resolution shell: 2.07–
2.00 A˚ for the native data set or 2.38–2.30 A˚ for the EMP data set.
b Rsym = 100 3 S jI 2 <I>j/S I.
c Phasing is based on two mercury sites in the asymmetric unit.
d Atomic model of SOCS3D-gp130 includes 1,044 protein atoms, 2
arsenic atoms, and 56 water molecules.
e Rcryst = 1003 S kFoj2 jFck/S jFoj, where Fo and Fc are the observed
and calculated structure factors, respectively (Fo > 0s). Rfree was de-
termined from 5% of the data.
f For bonded protein atoms.
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(A) Ribbon diagram of SOCS3Dwith the bound gp130 phosphopeptide shown in stick representation. The secondary structural elements for the
SH2 domain are labeled; a helices are colored purple, b strands are colored cyan, and loops are colored gray. Carbon atoms in the gp130 phos-
phopeptide are colored yellow, oxygen atoms are red, nitrogen atoms are blue, and the phosphate atom is black. The gray spheres represent
disordered residues in the BG loop. The N and C termini for the SH2 domain and the phosphopeptide are indicated by N and C, respectively, in
gray (SOCS3D) and yellow (gp130). The right panel is a view from 90 as indicated; the EF and BG loops are labeled, and the side chain of Tyr31
(on edge) of the kinase inhibitory region is shown. This panel and Figures 2A, 2B, 3B, and 3C were rendered with PyMOL (http://pymol.
sourceforge.net).
(B) Molecular surface representation of SOCS3D colored according to electrostatic potential (blue, positive [+10 kT]; white, neutral; red, negative
[210 kT]). Residues of the gp130 phosphopeptide are labeled relative to pTyr757 (P). The course of the EF loop in the SH2 domain is shown in
gray. This panel was rendered with GRASP (Nicholls et al., 1991).3 residue b strands, bBG1 (residues 165–167) and bBG2
(residues 174–176), which, along with residues Thr759
(P+2) through Val761 (P+4) of the gp130 phosphopep-
tide, create a mini three-stranded antiparallel b sheet
(Figure 1A).
Despite the length of the BG loop, the SOCS3 SH2 do-
main ends like a conventional SH2 domain with the short
bG (residues 180–182). This will necessarily position the
40 residue SOCS box, which directly follows (3 residue
linker), on the backside of the SH2 domain, opposite the
phosphopeptide binding surface (Figure 1A, right). Thus,
it is likely that phosphotyrosine binding by the SH2 do-
main and elongin BC engagement by the SOCS box
are independent recognition events for SOCS proteins.Determinants of SOCS3 Binding Specificity
The crystal structure of the SOCS3D-gp130 phospho-
peptide complex provides the molecular basis for un-
derstanding the phosphotyrosine binding preferences
of SOCS3. In a previous biochemical study (Nicholson
et al., 2000), individual alanine substitutions of Val760
(P+3), Val761 (P+4), and His762 (P+5) resulted in 31-,
10-, and 7-fold losses of binding to SOCS3, respectively,
and binding was effectively abrogated with substitution
of pTyr757 (P) with tyrosine. Substitution of either Val755
(P22) or Glu756 (P21) with alanine resulted in a 5-fold
loss of binding. As described above, the structural
basis for the sequence selectivity at the P (pTyr757),
P+3 (Val760), and P+5 (His762) positions of the
Structure
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SOCS3D and the gp130(pTyr757) Phospho-
peptide
(A) Stereoview of the interactions in the phos-
phate binding pocket of the SOCS3 SH2 do-
main. Atom coloring is the same as in Figure 1;
carbon atoms of SOCS3D are colored
according to secondary structure (cyan,
b strand; purple, a helix; gray, loop). Water
molecules are shown as red spheres. Hydro-
gen bonds/salt bridges are represented by
dashed lines.
(B) Stereoview of the interactions in the vicin-
ity of the P+3 (Val760) binding pocket.
(C) Schematic diagram of the SOCS3D-gp130
phosphopeptide interactions. Dashed lines
represent hydrogen bonds or salt bridges,
and gray lines represent van der Waals con-
tacts (3.8 A˚ cutoff). Residue boxes are col-
ored yellow for gp130 residues and either
cyan (in b strands), purple (in a helices), or
gray (in loops) for SOCS3D residues. ‘‘W’’ rep-
resents a well-ordered, bridging (SOCS3-
gp130) water molecule.phosphopeptide is evident. The contribution to binding
of valine at P+4 (Val761) over alanine is likely due to
the propensity of valine (with branching at the Cb
atom) to adopt an extended backbone conformation
(Betancourt and Skolnick, 2004; Hu and Hubbard,
2005), rather than to van der Waals interactions (few, if
any) made by the Val761 side chain. The carboxylate
group of Glu756 (P21) is in the vicinity of Lys91 (bD3)
(see Figure 1B, positive potential near P21 residue), al-
though not formally within salt-bridging distance.
SOCS3 binding sites have been mapped on several
other cytokine receptors, including the leptin receptor
(pTyr985/1077) (Bjorbak et al., 2000; Eyckerman et al.,
2000) and the erythropoietin receptor (pTyr401) (Sasaki
et al., 2000). However, the affinity of SOCS3 for thesephosphorylation sites is considerably lower (>80-fold)
than for pTyr757 in gp130 (De Souza et al., 2002). Of
these other sites, pTyr985 in the leptin receptor has
the highest affinity (80-fold lower than gp130) (De Souza
et al., 2002), possessing a valine at P22 and a valine at
P+4, but less favorable residues at P21 (lysine), P+3
(leucine), and P+5 (serine). From the crystal structure,
the SOCS3 P+3 binding pocket is best fit with valine, al-
though isoleucine could be accommodated, but leucine
less so. This is in agreement with a degenerate phos-
phopeptide library study of SOCS3 specificity (De Souza
et al., 2002).
The SH2 domain of SOCS3 has been shown to have
overlapping phosphotyrosine sequence specificity
with the SH2 domains of SHP2 (De Souza et al., 2002)
Crystal Structure of SOCS3-gp130 Complex
1289Figure 3. Structure-Based Sequence Align-
ment and Structural Comparisons
(A) Structural alignment of murine SOCS3D
with the SH2 domains of human Src (PDB
code 1SPS) (Waksman et al., 1993), human
SHP2 (N-terminal SH2, PDB code 1AYA)
(Lee et al., 1994), and murine SOCS1 (pre-
dicted). Residues shaded in purple reside in
a helices, and residues shaded in cyan reside
in b strands. Disordered residues not in-
cluded in the atomic model are italicized.
The residues in the BG loop that were deleted
in the SOCS3D construct are shaded in gray.
Residues of the SOCS3 and SOCS1 kinase in-
hibitory region are underlined. Residues col-
ored blue make direct hydrogen bonds or
salt bridges via their side chains to the phos-
phate group of the bound phosphopeptide
(predicted for SOCS1), and residues colored
red make direct hydrogen bonds via their
side chains to other residues in the bound
phosphopeptide (only present in SOCS3D-
gp130).
(B) Superposition (Ca trace) of the SOCS3D-
gp130(pTyr757) structure with the N-terminal
SH2 domain of SHP2 with bound phospho-
peptide (PDB code 1AYA) (Lee et al., 1994).
Residues in bB, bC, and bD were used in the
superposition (rmsd = 0.28 A˚ for 20 Ca
atoms). SOCS3D is colored cyan, the gp130
phosphopeptide is colored yellow, the SHP2
N-terminal SH2 domain is colored dark green,
and the bound phosphopeptide is colored
light green. Select side chains of the phos-
phopeptides are shown in stick representa-
tion: Val (P22), pTyr (P), Val (P+3), and His
(P+5) (SOCS3 structure) or Pro (P+5) (SHP2
structure).
(C) Superposition (Ca trace) of the SOCS3D-
gp130(pTyr757) crystal structure and the
SOCS3-gp130(pTyr757) NMR structure
(PDB code 2BBU) (Babon et al., 2006). The in-
dividual NMR structure with the lowest over-
all rmsd (#18 in the 20-structure ensemble;
rmsd = 4.3 A˚ for 115 Ca atoms) was used for
the comparison. For the figure, residues in
bB, bC, and bD were superimposed (rmsd =
1.4 A˚ for 23 Ca atoms). SOCS3D and the
gp130 phosphopeptide from the crystal
structure are colored cyan and yellow, re-
spectively, and SOCS3 and the gp130 phos-
phopeptide from the NMR structure are col-
ored dark green and light green, respectively. For clarity, the w30 residue PEST sequence at the beginning of the BG loop has been omitted
from the NMR structure. The beginning/end of the omitted interval are indicated by green arrows, and the beginning/end of the disordered region
of the BG loop in the SOCS3D crystal structure are indicated by cyan arrows. As in (A), select side chains of the phosphopeptide are shown in
stick representation.(see Figure 3B for a structural comparison). The resi-
dues chiefly responsible for the overlap are valine at
P22 (because of the common glycine at aA2) and va-
line/isoleucine at P+3. Despite the presence of these res-
idues in the sequence surrounding pTyr757 of gp130, the
affinity of the interaction of gp130 with the N- and C-ter-
minal SH2 domains of SHP2 is, respectively, 4- and 8-
fold lower than for SOCS3. In addition to the overall affin-
ity boost afforded by the interaction of the SOCS3 EF
loop with the phosphopeptide backbone (Figures 2B
and 2C), His762 (P+5) is likely to be a key determinant
in SOCS3 versus SHP2 binding. According to the phos-
phopeptide library study (De Souza et al., 2002), histidine
ranks highest at P+5 for SOCS3, whereas tryptophan and
phenylalanine are preferred at P+5 for SHP2 (both SH2domains). The crystal structure shows precisely why
SOCS3 prefers histidine at the P+5 position (Figures 2B
and 2C).
An NMR solution structure of SOCS3 with bound
gp130 pTyr757 phosphopeptide was recently reported
(Babon et al., 2006). Although this structure provides
an overall view of the SOCS3 SH2 domain and N-termi-
nal extension, there are significant deviations from the
crystal structure (Figure 3C); the overall root-mean-
square deviation (rmsd) in Ca positions is 4.5 A˚ (115 Ca
atoms, using the averaged NMR structure from 20 indi-
vidual structures). An important difference between the
X-ray and NMR structures concerns the SOCS3 EF loop.
In the NMR structure, there is no indication of an interac-
tion between the EF loop and the phosphopeptide
Structure
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tensive contacts (Figures 2B and 2C), which provide the
structural basis for high-affinity binding of gp130. Re-
moving from the superposition the EF loop and regions
C-terminal (e.g., aB, BG loop), the rmsd value for the
N-terminal 74 Ca atoms is still 3.6 A˚ (using the averaged
NMR structure). A recent crystal structure of SOCS2 in
complex with elongin BC (but without bound phospho-
peptide) (Bullock et al., 2006) reveals an SH2 domain
architecture that is very similar, up to the EF loop, to
that of the SOCS3D crystal structure, with an rmsd value
of only 1.3 A˚ for the same N-terminal 74 Ca atoms (45%
sequence identity).
Implications for JAK2 Inhibition by SOCS3
and SOCS1
Tyr31 of SOCS3, which has been postulated to function
as a pseudosubstrate inhibitor of JAK2 (Yasukawa et al.,
1999), is positioned near the beginning of aN, the N-ter-
minal extension to the SH2 domain (Figure 1A, right).
Based on manual docking of SOCS3D to previously
mapped pTyr1007 (Sasaki et al., 1999; Yasukawa et al.,
1999) in the activation loop of the JAK2 kinase domain
(Lucet et al., 2006), it is implausible that Tyr31 or the
equivalent residue in SOCS1, Tyr65, could reach the ac-
tive site of a JAK2 molecule to which its SH2 domain is
bound, i.e., in cis. In the case of the verified pseudosub-
strate inhibition of the insulin receptor kinase by Grb14
(Depetris et al., 2005), the pseudosubstrate residue
(Leu376) is 63 residues N-terminal to the start of the
SH2 domain, compared to just 15 residues for Tyr31 of
SOCS3. However, a pseudosubstrate inhibition mecha-
nism in trans, involving two JAK2 molecules, cannot be
ruled out. Moreover, from the SOCS3D-JAK2 docking
exercise, the EF and BG loop extensions in SOCS3,
which are not present in SOCS1—indeed, the SOCS1
BG loop is anomalously short (Figure 3A)—would likely
hinder binding of the SOCS3 SH2 domain to the intact
activation loop of JAK2. This observation is consistent
with the measured lower affinity for JAK2 of the
SOCS3 versus SOCS1 SH2 domain (Sasaki et al., 1999).
Based on the crystal structure of SOCS3D-
gp130(pTyr757) and the above-described structural
considerations, the physiologic target of the SOCS3
SH2 domain is likely to be pTyr757 of gp130 (and possi-
bly related sequences on other cytokine receptors)
rather than the activation loop of JAK2. Although the
exact mechanism by which SOCS3 inhibits JAK signal-
ing is not fully resolved, one favorable hypothesis is
that binding of the SOCS3 SH2 domain to pTyr757 of
gp130 positions the kinase inhibitory region (pseudo-
substrate or otherwise) for binding to a JAK2 molecule
bound to the same gp130 receptor. Additional biochem-
ical and structural studies will be necessary to validate
this particular ‘‘cis’’ mechanism and to elucidate the
precise structural mechanism by which the kinase
inhibitory region of SOCS3/1 represses JAK2 catalytic
activity.
Experimental Procedures
Protein Expression and Purification
Residues 15–185 of murine SOCS3 was subcloned from a full-length
SOCS3 cDNA kindly provided by Dr. E. Van Obberghen. The BG loopdeletion (residues 131–153) was introduced by PCR amplification of
the N-terminal (residues 15–130) and C-terminal (residues 154–185)
fragments separately, and then by using a mixture of the two frag-
ments as templates for PCR amplification from residue 15 to residue
185. The construct was verified by automated DNA sequencing.
SOCS3Dwas inserted into an E. coli expression vector that includes
a TEV-cleavable, N-terminal 6xHis tag. After TEV cleavage, 4 resi-
dues (GSEF) remain N-terminal to the start of the native SOCS3
sequence.
The vector encoding SOCS3D was transformed into E. coli strain
BL21(DE3), and cultures were grown in Luria broth media at 37C
to an OD600 of 0.6. Protein expression was induced by the addition
of isopropyl-thiogalactopyranoside (IPTG, 0.2 mM) for 12 hr at
19C. Cells were harvested, resuspended in lysis buffer (50 mM
Tris [pH 8.0], 300 mM NaCl, 0.1% Triton X-100, 2 mg/ml aprotinin,
50 mg/ml antipain, 1 mg/ml leupeptin, and 5 mM 2-mercaptoethanol),
and lysed by French press. The lysate was centrifuged at 37,0003 g
for 1 hr, and the supernatant was collected. Although SOCS3D is
mostly insoluble (inclusion bodies), the soluble fraction was purified
by Ni-NTA chromatography (Qiagen), followed by gel filtration chro-
matography (Superdex 75, Amersham). The 6xHis tag was then
cleaved with TEV, and the purified SOCS3D was separated from
the 6xHis tag and 6xHis-tagged TEV by passing the solution over
the Ni-NTA beads. An 11 residue phosphopeptide representing the
murine gp130 pTyr757 site, STVEpYSTVVHS, was synthesized
(GeneMed Synthesis) and solubilized in 100 mM Tris-HCl (pH 8.0)
and 150 mM NaCl. The phosphopeptide was added to SOCS3D
at a 2:1 molar stoichiometry prior to concentration in a Vivaspin
(Vivascience) microconcentrator.
Crystallization, X-Ray Data Collection, Structure Determination,
and Refinement
Crystals of the SOCS3D-gp130 phosphopeptide complex were
grown at 20C by using the hanging drop vapor diffusion method.
A total of 1 ml of a stock solution of the complex at 7–12 mg/ml
with a w2:1 molar excess of phosphopeptide was mixed with an
equal volume of reservoir buffer containing 30% PEG 8000, 0.1 M so-
dium cacodylate (pH 6.5), and 0.2 M sodium acetate (Hampton Re-
search Crystal Screen condition #28). The crystals belong to ortho-
rhombic space group C2221 with cell dimensions of a = 42.92 A˚, b =
94.71 A˚, and c = 69.92 A˚. There is one complex in the asymmetric
unit, yielding a solvent content of 37%.
An initial 3.2 A˚ resolution data set was collected on a rotating an-
ode source (Rigaku RU-200 generator, Rigaku R-AXIS IIC image
plate detector, and Rigaku Confocal Blue optics) and processed
by using HKL-2000 (Otwinowski and Minor, 1997). Previous bio-
chemical studies had indicated that the SOCS3 SH2 domain and
the C-terminal SH2 domain of SHP2 had overlapping phosphotyro-
sine binding specificities (Nicholson et al., 2000). Using the structure
of the C-terminal SH2 domain of SHP2 (PDB code 2SHP [Hof et al.,
1998]) as a template, a model for the SOCS3 SH2 domain was gen-
erated by using SWISS-MODEL (Schwede et al., 2003). The model
included SOCS3 residues 46–182, with residues 106–114 (EF loop)
and residues 131–175 (BG loop) omitted. Using this as a search
model, a molecular replacement solution was found with AMoRe
(Navaza, 1994). The initial AMoRe solution gave a correlation coeffi-
cient (c.c.) of 30.5% and an R value of 47.8% (highest 85% of the
structure factor amplitudes, 12.0–3.5 A˚), with the next highest solu-
tion at c.c. = 26.9% (R value = 48.0%). By deleting several residues in
other loop segments, a c.c. of 32.0% (R value of 47.8%) was
achieved (next highest solution: c.c. = 26.9%, R value = 48.8%). Us-
ing subsequent data sets at 2.7 A˚ resolution (rotating anode) and
2.0 A˚ resolution (NSLS beam line X4A; see Table 1), an atomic model
for SOCS3D was generated from iterative rounds of building in O
(Jones et al., 1991) and refinement (simulated annealing and posi-
tional/B factor) with CNS (Bru¨nger et al., 1998). The final rounds of
refinement were performed with REFMAC (Murshudov et al.,
1997). The model for SOCS3D includes residues 29–185 (residues
15–28 are disordered), except for residues 131–153 (BG loop, dele-
tion), residues 155–163 (BG loop, disordered), and residues 169–172
(BG loop, disordered).
At an intermediate stage of structure building and refinement
(R value/Rfree ofw30/34%), experimental phasing was sought. Mer-
cury-derivatized SOCS3D-gp130 crystals were produced by
Crystal Structure of SOCS3-gp130 Complex
1291soaking overnight in reservoir solution (described above) containing
1 mM ethylmercuric phosphate (EMP). The derivatized crystals were
subsequently soaked in cryosolution (25% PEG 8000, 0.1 M sodium
cacodylate [pH 6.5], 0.2 M sodium acetate, and 20% ethylene glycol)
for 5 min to remove nonspecifically bound EMP. The crystal was
then flash frozen in liquid nitrogen. A 2.3 A˚ data set at l = 1.0055 A˚
(just above the mercury LIII absorption edge) was collected from
a single EMP-derivatized crystal at NSLS beam line X4A (Table 1).
Data were indexed, integrated, and scaled with HKL-2000 (Otwinow-
ski and Minor, 1997). The native and EMP-derivatized crystals were
isomorphous. Two mercury atoms in the asymmetric unit, bound to
Cys97 and Cys119, were located by using SOLVE (Terwilliger and
Berendzen, 1999). SIRAS (single isomorphous replacement with
anomalous scattering) experimental phases were calculated to 2.5
A˚ resolution with MLPHARE (Otwinowski, 1991) by using the 2.3 A˚
EMP data set and the 2.0 A˚ native data set. After real-space density
modification in RESOLVE (Terwilliger and Berendzen, 1999), the ex-
perimentally phased electron density map was of high quality and
confirmed that the structure built by using model-derived phases
(from the molecular replacement solution) was correct, and that
much of the N-terminal region, as well as significant portions of
the BG loop, was disordered. Buried surface areas in SH2-phospho-
peptide complexes were computed by using CNS (Bru¨nger et al.,
1998) (buried_surface.inp) with a probe radius of 1.4 A˚ (water mole-
cules removed). Structural superpositions were performed with
TOSS (Hendrickson, 1979).
Supplemental Data
Supplemental Data include isothermal titration calorimetry results
and are available at http://www.structure.org/cgi/content/full/14/8/
1285/DC1/.
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